FDA's New Digital Health Advisory Committee
Summary
On October 11, 2023, the FDA announced the creation of a new advisory committee on digital health technologies (DHTs), including technologies that employ AI/machine learning. The new Digital Health Advisory Committee will advise FDA on the benefits, risks and clinical outcomes associated with the use of DHTs. The Committee will help to ensure digital health medical devices are designed and targeted to meet the needs of diverse populations, and further FDA’s goal of advancing health equity. FDA plans for the Committee to be fully operational in 2024.
Impacted Sectors
Additional Information
© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.